Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Account Payables: 2009-2024

Historic Change in Account Payables for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $1.8 million.

  • Catalyst Pharmaceuticals' Change in Account Payables fell 19.77% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 million, marking a year-over-year decrease of 135.42%. This contributed to the annual value of $1.8 million for FY2024, which is 83.38% down from last year.
  • As of FY2024, Catalyst Pharmaceuticals' Change in Account Payables stood at $1.8 million, which was down 83.38% from $10.8 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Change in Account Payables ranged from a high of $10.8 million in FY2023 and a low of -$1.5 million during FY2021.
  • In the last 3 years, Catalyst Pharmaceuticals' Change in Account Payables had a median value of $1.8 million in 2024 and averaged $4.6 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Change in Account Payables plummeted by 1,178.26% in 2021 and then surged by 796.44% in 2023.
  • Yearly analysis of 5 years shows Catalyst Pharmaceuticals' Change in Account Payables stood at $138,000 in 2020, then crashed by 1,178.26% to -$1.5 million in 2021, then surged by 181.12% to $1.2 million in 2022, then surged by 796.44% to $10.8 million in 2023, then crashed by 83.38% to $1.8 million in 2024.